These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 18401585)

  • 1. The face of high risk prostate cancer.
    Albertsen PC
    World J Urol; 2008 Jun; 26(3):205-10. PubMed ID: 18401585
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer.
    Albertsen PC; Hanley JA; Gleason DF; Barry MJ
    JAMA; 1998 Sep; 280(11):975-80. PubMed ID: 9749479
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of Cancer Specific Mortality with Surgery versus Radiation as Primary Therapy for Localized High Grade Prostate Cancer in Men Younger Than 60 Years.
    Huang H; Muscatelli S; Naslund M; Badiyan SN; Kaiser A; Siddiqui MM
    J Urol; 2019 Jan; 201(1):120-128. PubMed ID: 30059685
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prostate cancer and the Will Rogers phenomenon.
    Albertsen PC; Hanley JA; Barrows GH; Penson DF; Kowalczyk PD; Sanders MM; Fine J
    J Natl Cancer Inst; 2005 Sep; 97(17):1248-53. PubMed ID: 16145045
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): an open-label, randomised, phase 3 factorial trial.
    Denham JW; Joseph D; Lamb DS; Spry NA; Duchesne G; Matthews J; Atkinson C; Tai KH; Christie D; Kenny L; Turner S; Gogna NK; Diamond T; Delahunt B; Oldmeadow C; Attia J; Steigler A
    Lancet Oncol; 2014 Sep; 15(10):1076-89. PubMed ID: 25130995
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical predictors of upgrading to Gleason grade 4 or 5 disease at radical prostatectomy: potential implications for patient selection for radiation and androgen suppression therapy.
    D'Amico AV; Renshaw AA; Arsenault L; Schultz D; Richie JP
    Int J Radiat Oncol Biol Phys; 1999 Nov; 45(4):841-6. PubMed ID: 10571187
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 20-year outcomes following conservative management of clinically localized prostate cancer.
    Albertsen PC; Hanley JA; Fine J
    JAMA; 2005 May; 293(17):2095-101. PubMed ID: 15870412
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term survival among men with conservatively treated localized prostate cancer.
    Albertsen PC; Fryback DG; Storer BE; Kolon TF; Fine J
    JAMA; 1995 Aug 23-30; 274(8):626-31. PubMed ID: 7637143
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of localised prostate cancer: watchful waiting, surgery or radiation therapy, depending on the natural course, which is often relatively slow.
    Prescrire Int; 2012 Oct; 21(131):242-8. PubMed ID: 23185849
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Active Surveillance of Grade Group 1 Prostate Cancer: Long-term Outcomes from a Large Prospective Cohort.
    Tosoian JJ; Mamawala M; Epstein JI; Landis P; Macura KJ; Simopoulos DN; Carter HB; Gorin MA
    Eur Urol; 2020 Jun; 77(6):675-682. PubMed ID: 31918957
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PSA failure following definitive treatment of prostate cancer having biopsy Gleason score 7 with tertiary grade 5.
    Patel AA; Chen MH; Renshaw AA; D'Amico AV
    JAMA; 2007 Oct; 298(13):1533-8. PubMed ID: 17911498
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk-stratification based on magnetic resonance imaging and prostate-specific antigen density may reduce unnecessary follow-up biopsy procedures in men on active surveillance for low-risk prostate cancer.
    Alberts AR; Roobol MJ; Drost FH; van Leenders GJ; Bokhorst LP; Bangma CH; Schoots IG
    BJU Int; 2017 Oct; 120(4):511-519. PubMed ID: 28267899
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Global update on defining and treating high-risk localized prostate cancer with leuprorelin: a USA perspective--identifying men at diagnosis who are at high risk of prostate cancer death after surgery or radiation therapy.
    D'Amico A
    BJU Int; 2007 Jan; 99 Suppl 1():13-6; discussion 17-8. PubMed ID: 17229162
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identifying men diagnosed with clinically localized prostate cancer who are at high risk for death from prostate cancer.
    D'Amico AV; Hui-Chen M; Renshaw AA; Sussman B; Roehl KA; Catalona WJ
    J Urol; 2006 Dec; 176(6 Pt 2):S11-5. PubMed ID: 17084157
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radical prostatectomy represents an effective treatment in patients with specimen-confined high pathological Gleason score prostate cancer.
    Lughezzani G; Gallina A; Larcher A; Briganti A; Capitanio U; Suardi N; Lista G; Abrate A; Sangalli MN; Buffi N; Cestari A; Guazzoni G; Rigatti P; Montorsi F
    BJU Int; 2013 May; 111(5):723-30. PubMed ID: 22487441
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prostate-specific antigen control with low-dose adjuvant radiotherapy for high-risk prostate cancer.
    Macdonald OK; Lee RJ; Snow G; Lee CM; Tward JD; Middleton AW; Middleton GW; Sause WT
    Urology; 2007 Feb; 69(2):295-9. PubMed ID: 17320667
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prostate biopsy: who, how and when. An update.
    Djavan B; Milani S; Remzi M
    Can J Urol; 2005 Feb; 12 Suppl 1():44-8; discussion 99-100. PubMed ID: 15780165
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oncologic outcomes at 10 years following robotic radical prostatectomy.
    Diaz M; Peabody JO; Kapoor V; Sammon J; Rogers CG; Stricker H; Lane Z; Gupta N; Bhandari M; Menon M
    Eur Urol; 2015 Jun; 67(6):1168-1176. PubMed ID: 24996687
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcomes of initially expectantly managed patients with low or intermediate risk screen-detected localized prostate cancer.
    Bul M; van den Bergh RC; Zhu X; Rannikko A; Vasarainen H; Bangma CH; Schröder FH; Roobol MJ
    BJU Int; 2012 Dec; 110(11):1672-7. PubMed ID: 22928973
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pathological and biochemical outcomes after radical prostatectomy in men with low-risk prostate cancer meeting the Prostate Cancer International: Active Surveillance criteria.
    Mitsuzuka K; Narita S; Koie T; Kaiho Y; Tsuchiya N; Yoneyama T; Kakoi N; Kawamura S; Tochigi T; Habuchi T; Ohyama C; Arai Y
    BJU Int; 2013 May; 111(6):914-20. PubMed ID: 23320782
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.